RADICAVA ORS gives people with ALS an oral treatment option that offers the same efficacy as the IV formulation of edaravone1 JERSEY CITY, N.J., June 15, 2022 — Mitsubishi Tanabe …
Topic:
radicava®
-
-
Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA® (edaravone) at 2022 American Academy of Neurology Annual Meeting
by Your NewsAnalysis Suggests Use of RADICAVA IV is Associated with Improved Survival in People with ALS JERSEY CITY, N.J., April 4, 2022 — Mitsubishi Tanabe Pharma America, Inc. (MTPA) today …